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Abstract
AIM: To evaluate the effectiveness and safety of 
oral N-acetyl-L-cysteine (NAC) co-administration with 
mesalamine in ulcerative colitis (UC) patients.
METHODS: Thirty seven patients with mild to moderate 
UC were randomized to receive a four-wk course of oral 
mesalamine (2.4 g/d) plus N-acetyl-L-cysteine (0.8 g/d) 
(group A) or mesalamine plus placebo (group B). 
Patients were monitored using the Modified Truelove-
Witts Severity Index (MTWSI). The primary endpoint 
was clinical remission (MTWSI ≤ 2) at 4 wk. Secondary 
endpoints were clinical response (defined as a reduction 
from baseline in the MTWSI of ≥ 2 points) and drug 
safety. The serum TNF-α, interleukin-6, interleukin-8 
and MCP-1 were evaluated at baseline and at 4 wk of 
treatment.
RESULTS: Analysis per-protocol criteria showed clinical 
remission rates of 63% and 50% after 4 wk treatment 
with mesalamine plus N-acetyl-L-cysteine (group A) and 
mesalamine plus placebo (group B) respectively (OR = 1.71; 
95% CI: 0.46 to 6.36; P = 0.19; NNT = 7.7). Analysis of 
variance (ANOVA) of data indicated a significant reduction 
of MTWSI in group A (P = 0.046) with respect to basal 
condition without significant changes in the group B 
(P = 0.735) during treatment. Clinical responses were 
66% (group A) vs 44% (group B) after 4 wk of treatment 
(OR = 2.5; 95% CI: 0.64 to 9.65; P = 0.11; NNT = 4.5). 
Clinical improvement in group A correlated with a decrease 
of IL-8 and MCP-1. Rates of adverse events did not differ 
significantly between both groups. 
CONCLUSION: In group A (oral NAC combined with 
mesalamine) contrarily to group B (mesalamine alone), 
the clinical improvement correlates with a decrease of 
chemokines such as MCP-1 and IL-8. NAC addition not 
produced any side effects.
© 2008 WJG. All rights reserved.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic idiopathic inflammatory 
disease of  the colon characterized by rectal bleeding, 
diar rhea, abdominal pain, weight loss and fever [1]. 
Histological examination of  biopsy specimens reveals 
the presence of  infiltrated white blood cells such as 
neutrophils, monocytes and lymphocytes in the colonic 
interstitium[2]. In the recruitment and activation of  white 
blood cells, participate cytokines [interleukin (IL)-1β, 
IL-2, IL-6, IL-12 and tumour necrosis factor-alpha][3], 
chemokines [IL-8, monocyte chemoattractant protein 
(MCP)-1 and MCP-3] [4], cell adhesion molecules [5] as 
well as the inducible isoforms of  nitric oxide synthase[6] 
and cyclooxygenase [7]. Moreover, the infiltration of  
phagocytes results in the stimulation of  the latent plasma 
membrane associated NADPH oxidase, which release 
large amounts of  superoxide (O2) and H2O2, producing 
hydroxyl radicals[8]. 
Recently, a new hypothesis termed “Radical Induction 
Theory” has been proposed to explain the etiology of  
UC[9]. The excess of  un-neutralized hydrogen peroxide 
(H2O2), produced within colonic epithelial cells as a 
result of  aberrant cellular metabolism, diffuses through 
cell membranes to the extracellular space, where it is 
converted to the highly damaging hydroxyl radical (OH) 
resulting in oxidative damage to structures comprising 
the colonic epithelial barrier. Once damaged, the barrier 
is unable to exclude highly immunogenic fecal bacteria 
invading the normally sterile submucosa. This antigen 
exposure provokes an initial immune response of  white 
blood cell infiltration into colonic mucosa. The injurious 
“reactive oxygen species” would be inactivated by 
protective enzymes (superoxide dismutase, catalase and 
glutathione peroxidase) and by non-enzymatic antioxidants 
(glutathione, ascorbate and α-tocopherol)[10,11]. A common 
feature of  patients with inflammatory bowel disease is 
a depletion of  endogenous oxidant defenses such as 
ascorbate, β-carotene, α-tocopherol and glutathione[12,13]. 
This last compound is a naturally occurring tripeptide 
(γ-Glu-Cys-Gly) found in high concentrations within 
tissues. In experimental acute colitis, cellular glutathione 
levels decreased significantly and the administration 
of  the antioxidant N-acetyl-L-cysteine (NAC) restored 
glutathione level and decreased colonic inflammation[14]. 
More recently it has been showed that the combination 
of  NAC and mesalamine accelerates mucosal healing in 
a rodent model of  colitis[15]. Taken together, these results 
suggest an imbalance and inefficient endogenous antioxidant 
response in the intestinal mucosa of  UC patients, which 
may contribute to the etiology, the pathogenesis and the 
perpetuation of  the inflammatory processes[10]. The aim 
of  the present pilot study was to evaluate the possible 
effectiveness and safety of  NAC associated with mesalamine 
in mild to moderate UC. 
MATERIALS AND METHODS
Patient’s selection criteria and study protocol
Thirty seven patients with mild to moderate UC according 
to the Modified Truelove and Witts Severity Index 
(MTWSI)[16] were randomized to receive a 4-wk course of  
oral mesalamine (2.4 g/d) plus N-acetyl-L-cysteine (NAC) 
(0.8 g/d) (group A) or mesalamine plus placebo (group 
B). Exclusion criteria were age over 70 or less 18 years, 
pregnancy, serious underlying systemic diseases and 
MTWSI > 10. Treatment with oral or topical steroids, 
topical mesalamine, immunosuppressors (azathioprine, 
6-mercaptopurine, etc.) or antioxidants was discontinued 
at least three weeks before commencement of  the trial. 
The protocol was approved by the Ethical Investigation 
Committee of  the corresponding Institutions, and written 
informed consent was obtained from all the patients. 
Diagnosis of  UC was established by standard clinical, 
radiological, histological, and endoscopic criteria [1]. 
The patient’s characteristics are described in Table 1. 
Patients were allocated to one of  two treatment groups 
according to a centrally computer-assisted randomization 
list and received oral mesalamine at a dose of  2.4 g/d 
combined with NAC at a dose of  0.8 g/d (group A) or oral 
mesalamine at a dose of  2.4 g/d and placebo (group B) 
during four wk. NAC was provided as 200 mg sacks of  
water-soluble powder identical in taste, bulk and appearance 
to those of  placebo. Mesalamine was provided as an 800 mg 
tablets coated with 1:2 copolymer of  metacrylic acid and 
methylmethacrylate (Eudragit-S) used for colonic delivery 
of  mesalamine[17]. 
Measurement of disease activity
Clinical and biochemical findings were assessed by the 
gastroenterologist at intervals of  two and four weeks 
respectively. All patients were asked to record stool 
frequency (number of  daily stools) and consistency, 
nocturnal stools, visible blood in stool, fecal incontinence, 
abdominal pain, abdominal tenderness, need for 
antidiarrheals and a patient self-rating evaluation based 
upon the impact of  symptoms on normal life activities. 
For stool frequency and abdominal pain, a scale from 
0 (normal) to 4 (markedly abnormal) was used. For use of  
antidiarrheal medication, a scale from 0 (no) to 1 (yes) was 
used. For the other parameters, the scale ranged from 0 
(normal) to 3 (markedly abnormal). The Modified Truelove-
Witts Severity Index, which has been considered useful in 
therapeutic trials[16], was calculated from these data. The 
primary endpoint was clinical remission (MTWSI ≤ 2) at 
4 wk. Secondary endpoints were clinical response (defined 
as a reduction from baseline in the MTWSI of  ≥ 2 points) 
and drug safety.
Assessment of safety
The hematological and biochemical studies were performed 
at regular intervals by the analytical laboratory services 
of  the corresponding hospitals: complete blood count, 
hepatic enzymes, bilirubin, erythrocyte sedimentation 
rate and C-reactive protein were measured between other 
biochemical parameters. 
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Evaluation of reduced glutathione, TNF-α, IL-6, IL-8 and 
MCP-1 circulating levels
Blood samples were obtained by venipuncture and placed 
into tubes containing lithium heparin as anticoagulant. 
For the measurement of  GSH in whole-blood samples, 
0.5 mL of  blood was treated immediately with 0.25 mL 
of  trichloroacetic acid (12%) on ice. After 5 min tubes 
were centrifuged at 13 000 g during 10 min at 4℃ and 
the acidic supernatants were immediately used for GSH 
measure. GSH determinations were performed as described 
previously[18] with some modifications. Briefly, the amount 
of  lactoyl-glutathione formed between methylglyoxal 
(110 mmol/L) and GSH in presence of  glyoxalase-I (lactoyl-
glutathione lyase) at pH 7.0 buffered with 0.1mmol/L 
sodium phosphate was measured spectro-photometrically at 
240 nm.
The concentration of  IL-8, MCP-1, TNF-α and 
IL-6 present in plasma was determined by using specific 
sandwich ELISA following manufacturer protocol. 
Briefly plates (Costar) were coated overnight at 4℃ with 
specific mouse anti-human monoclonal antibody (Becton 
Dickinson) in 0.1 mol/L Na2HPO4 (pH 9) (dilution 
1:200). After washing with PBS containing 0.5% Tween 20 
unspecific sites were blocked with PBS containing 3% BSA. 
Plasma was added to each well and incubated for 12 h at 4℃. 
Unbound material was discarded and biotinylated mouse 
anti-human monoclonal antibody (Becton Dickinson) was 
incubated during 1 h at room temperature. After washing 
bound antibodies were detected by incubation with avidin-
peroxidase (Sigma) for 30 min in presence of  the 2,2 
azinobis (3-ethybenzthiazolinesulfonic acid) (ABTS of  
Sigma) as substrate. Absorbance was measured at 405 nm. 
A Standard curve was constructed for each cytokine or/and 
chemokines by using recombinant human molecules (Becton 
Dickinson) in PBS containing 3% BSA. 
Statistical analysis
For quantitative variables, mean and standard deviation 
were calculated. Statistical analysis was performed with 
the SAS program. For the comparison of  treatment effect 
on Modified Truelove-Witts Severity Index between both 
groups of  patients, the analysis of  covariance (ANCOVA) 
was used after adjusting for baseline values. To study the 
evolution of  disease score for each group, the analysis 
of  variance (ANOVA) with Bonferroni corrected post hoc 
comparisons was used to determine significant treatment 
effects. P < 0.05 was considered statistically significant.
RESULTS
Thirty seven patients were included in the trial. All 
patients had mild to moderate UC according to the 
criteria of  Modified Truelove-Witts Severity Index[16]. 
Treatment groups were comparable at randomization 
for baseline demographic characteristics (Table 1). All 
patients completed the one month study (19 treated with 
mesalamine plus NAC and 18 treated with mesalamine 
plus placebo) following the correct protocol.
Treatment effect on Modified Truelove-Witts Severity Index
The disease score was calculated by “per-protocol” criteria, 
the data of  all randomized patients at 0, 2 and 4 wk of  
treatment were included. Twelve of  19 patients (63%) in 
the combination treatment group (A) underwent remission 
(score ≤ 2) at 4 wk of  treatment. At the same period of  
time nine of  18 patients (50%) in the mesalamine plus 
placebo group (B) underwent clinical remission (score ≤ 2). 
However, statistically not-significant differences were 
observed between both groups in this clinical parameter 
(OR = 1.71; 95% CI: 0.46 to 6.36; P = 0.19; NNT = 7.7). 
During 4 wk of  treatment, clinical response measured 
by MTWSI improved in group A compared with the 
corresponding baseline values (P = 0.046, ANOVA 
test) (Table 2). Whereas in the group B no statistical 
improvement were reached (P = 0.735, ANOVA test) 
at the same period of  time. Although a better favorable 
trend was observed with the combined therapy (group 
A) as compared to that observed in the mesalamine plus 
placebo arm (group B), the significance threshold was 
not reached (ANCOVA test). The disease score decreased 
in both groups of  patients at 4 wk of  treatment with 
respect to the corresponding baseline values, however, 
the group B was not statistically significant; the MTWSI 
change was 2.63 ± 0.82 (P = 0.004) and 0.89 ± 0.9 
(P = 0.33) (paired student’ t-test) at 4 wk of  treatment for 
A and B groups, respectively. 
Effect of treatment on reduced glutathione, TNF-α, IL-6, 
IL-8 and MCP-1 circulating levels
Measurement of  biochemical parameters was performed 
Table 1  Basal and demographic data
Data Group A 
Mesalamine
+ NAC (n  = 19)
Group B
Mesalamine
+ placebo (n  = 18)
Total
(n  = 37)
Age (mean ± SD) 51.4 ± 14 42.2 ± 13 46.9 ± 14
White race, n (%) 11 (57.8) 13 (72.2) 24 (64.8)
Smoker, n (%)   2 (10.5)   3 (16.7)   5 (13.5)
Male, n (%)   8 (42.1)   5 (27.8) 13 (35.1)
Basal modified 
Truelove-Witts 
severity index
(mean ± SD)
           5.95 ± 2.22            4.61 ± 2.09      5.30 ± 2.20
NAC: N-acetyl-L-cysteine. 
Table 2  Changes in disease activity assessed using modified 
Truelove-Witts Severity Index (mean ± SD) in subjects who 
received the drugs for 2 wk and 4 wk
Week of treatment 0 2 4 ANOVA 
statistical test
(number of 
patients)
Group A mesalamine 
plus NAC
5.95 ± 2.22 4.68 ± 3.40 3.32 ± 3.71a P = 0.046
(n = 19)
Group B mesalamine 
plus placebo
4.61 ± 2.09 4.17 ± 3.85 3.72 ± 3.91 P = 0.735
(n = 18)
aP < 0.05 represents the significance levels compared with the corresponding 
basal values using the ANOVA statistical test. 
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at the beginning and at 4 wk of  treatment (Figure 1). 
Blood levels of  reduced glutathione (GSH) did not change 
significantly at 4 wk of  treatment in group A (NAC plus 
mesalamine) with respect to control group (placebo plus 
mesalamine). TNF-α plasma levels remained constant and 
did not change along the period studied in either group 
A or B. IL-6 plasma levels decreased slightly, although 
not significantly, in group A, without changes in the 
group B. By contrast, circulating levels of  IL-8 decreased 
significantly (P < 0.05), with respect to baseline values, at 4 
wk of  treatment in group A, without changes in the group 
B. The decrease in IL-8 coincided with the induction of  
remission of  the disease in group A. Finally, the profile of  
MCP-1 circulating levels was similar to that found for IL-8. 
Thus, at 4 wk of  treatment with NAC plus mesalamine 
(Group A), a significant (P < 0.05) decrease in MCP-1 
with respect to the corresponding baseline values was 
demonstrated, while statistically non-significant changes 
were observed in group B. 
Safety
No serious adverse effects, clinical or analytical, were 
observed in either treatment group. The hematological and 
biochemical results at baseline and 4 wk are summarized in 
Tables 3 and 4 respectively.
DISCUSSION
The idea that NAC treatment could be useful in UC 
emerged from previous studies in animal models of  that 
disease[14]. Very recently it has been showed that antioxidant 
therapy with NAC plus mesalamine accelerates mucosal 
healing in rodent model of  colitis[15]. Mucosal biopsies 
taken from active gut inflammation sites from UC patients 
produced significantly more reactive oxygen species 
(H2O2 and superoxide) compared to either uninvolved or 
healthy tissue[10,19]. Glutathione and glutathione peroxidase 
are the most important system for elimination of  H2O2. 
Consequently, the reduced glutathione levels in the inflamed 
mucosa from patients with UC could be decreased[12,13]. The 
oral treatment with NAC (a precursor of  glutathione) of  
UC patients could restore the circulating and local levels of  
reduced glutathione to respond to the excess of  reactive 
oxygen species. Recently, the effectiveness of  antioxidant 
therapy in pediatric Cohn’s disease has been reported in an 
open-label pilot study[20].
Monitoring of  standard laboratory data of  our patients 
demonstrated no worsening of  the values with respect to 
baseline data during treatment (with or without NAC). 
Moreover, no significant differences in standard laboratory 
data were observed between the values of  the two 
treatment groups (Tables 3 and 4). Finally, no significant 
adverse events related with the NAC treatment occurred in 
any of  the patients.
Treatment with mesalamine was maintained constant 
throughout the study for all patients, with improvement of  
the disease measured by MTWSI. However in the group 
receiving a supplement of  NAC (0.8 g/d), a more favorable 
trend was seen with respect to mesalamine treatment 
alone. The mesalamine plus NAC group underwent a 
significant clinical response with respect to basal state 
measured by MTWSI at 4 wk of  treatment. However, in 
the control group (mesalamine plus placebo) no significant 
improvement was observed in the course of  the disease at 
that time. These results suggest that NAC could accelerate 
the healing process in UC. However, the conclusion could 
be affected as consequence of  non-homogeneity of  both 
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Figure 1  Reduced glutathione levels in whole blood and tumor necrosis factor 
alpha (TNF-α), interleukin IL-6, IL-8, and monocyte chemoattractant protein 
(MCP)-1 levels in plasma of subjects after 4 wk of treatment with mesalamine 
plus NAC (Group A) or mesalamine plus placebo (Group B). mean ± SD. 
aP < 0.05 represent the significance level compared with basal values using the 
Student' t-test.
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groups according to the age; a definite limitation of  this 
pilot trial is the small size of  the groups. This fact must be 
kept in mind for planning further studies (with higher doses 
of  NAC, route of  administration or larger sample size).
The beneficial effect of  NAC at 4 wk did not correlate 
with changes in reduced glutathione in blood, which 
suggests that the mechanism of  action of  NAC is local, and 
not systemic, at that time. Similar pharmacokinetic results 
were observed in the treatment with 0.6 g/d of  NAC of  
HIV infected patients, resulting in a glutathione increase 
at 8 wk of  treatment[21]. Although oral doses of  1.8 g/d 
of  NAC increased the percentage of  CD4 lymphocyte 
counts in HIV infected patients, it did not produce changes 
in plasma glutathione levels [22], only high oral doses 
(4-8 g/d of  NAC) of  this antioxidant could replenished 
glutathione levels and improved survival rates of  HIV 
infected patients[23]. Treatment with comparables doses 
(100 mg/kg NAC) of  acetic acid-induced experimental 
colitis substantially reduced the degree of  colonic injury. 
Lower doses (20 mg/kg) had no protective effect [24]. 
Moreover, clinical studies suggest liver absorption of  NAC 
when it is administered orally because hepatic clearance 
of  NAC decreased significantly during cirrhosis[25] and 
its metabolism improves hepatosplanchnic flow and liver 
function in septic shock patients[26]. In experimental colitis 
the beneficial effects of  NAC were observed by intrarectal 
and intraperitoneal administration[27]. For all these reasons, 
clinical trials have used higher doses of  NAC bypassing 
digestive tract without serious adverse events[28,29].
Our study also suggests that the beneficial effect 
of  NAC in UC is related to the down-regulation of  
chemokines such as MCP-1 and IL-8. At 4 wk of  treatment, 
both molecules decreased in plasma of  patients treated with 
NAC plus mesalamine, whereas in the mesalamine plus 
placebo group this change was not statistically significant. 
The induction of  the remission in the group A coincided 
with the decrease in IL-8 and MCP-1 plasma levels, 
suggesting that the effect of  NAC is related to the decrease 
of  molecules that activates the recruitment and activation 
of  neutrophils and monocytes to the inflamed mucosa. Our 
data are in concordance with previous studies performed 
in alcoholic hepatitis, where MCP-1 production stimulated 
by lipopolysaccharides decreased with NAC treatment, 
suggesting that the antioxidant act directly on target cells[30]. 
Previously, it was observed that the percentage of  cells 
expressing IL-8 and MCP-1 was significantly enhanced in 
UC samples as compared to controls[31]. Furthermore, the 
local overexpression of  MCP-1 and IL-8 was associated 
with inflammation in UC[32]. A close correlation has been 
demonstrated between mucosa IL-8 mRNA expression and 
the colonic inflammation in UC patients, and a decrease 
of  local IL-8 expression has been reported during UC 
improvement after granulocytapheresis[33]. Local changes 
in IL-8 expression correlates with urinary IL-8, and this 
chemokine increases around ten fold in the urine during 
active UC compared with control subjects[34], suggesting that 
circulating IL-8 is a good indirect marker for the assessment 
of  active inflammation in the colonic mucosa. Other pro-
inflammatory cytokines such as TNF-α and IL-6, previously 
implicated in inflammatory bowel diseases, did not change 
significantly in plasma with the treatment prescribed in our 
study. However we can not rule out the hypothesis that 
down-regulation of  TNF-α and IL-6 in the mucosa could 
explain the improvement observed.  
In conclusion, the results of  the present pilot study 
suggest that combined therapy (NAC and mesalamine) 
produces a clinical improvement of  UC patients which 
correlates with a decrease of  MCP-1 and IL8. However, 
the difference in clinical effect with respect to the control 
group (mesalamine alone) is not conclusive. NAC is safe 
and well tolerated. 
COMMENTS
Background
A new hypothesis termed “Radical Induction Theory” has been proposed to 
explain the etiology of ulcerative colitis (UC) (J Pravda. World J Gastroenterol 
2005; 11: 2371). The excess of hydrogen peroxide (H2O2) could damage the 
colonic epithelial barrier. In experimental acute colitis, cellular glutathione levels 
decreased and the administration of their precursor (N-acetyl-L-cysteine) (NAC) 
restore the endogenous level and decreased colonic inflammation. Recently, it has 
been showed that the combination of NAC and mesalamine accelerates mucosal 
healing in a rodent model of colitis (Siddiqui et al, Dig Dis Sci 2006; 51: 698).
Table 3  Hematological parameters
Group A Group B
Basal 4 wk Basal 4 wk
Haemoglobin (g/100 mL) 14.28 13.98 13.81 13.79
Haematocrit (g/100 mL) 42.55 42.01 40.50 40.61
Erythrocytes (× 106/mm3)   4.81   4.69   4.60   4.58
Platelet count (× 103/mm3)    232.95    249.84     263.22  260.50
VSG (mm/h) 17.13 15.00 19.60 17.38
Leukocytes (× 103/mm3)   7.14   7.06   7.86   7.90
Neutrophils (%) 62.63 61.45 63.75 58.61
Eosinophils (%)   2.56   3.34   3.81   3.22
Basophils (%)   0.32   0.55   0.44   0.22
Lymphocytes (%) 25.89 28.03 27.82 27.74
Monocytes (%)   6.97   7.20   7.14   7.88
Group A: Mesalamine + NAC; Group B: Mesalamine + placebo.
Table 4  Biochemical parameters
Group A Group B
Basal 4 wk Basal 4 wk
SGOT (units/L) 16.89 16.47 20.47 25.06
SGPT (units/L) 15.58 17.53 36.94 43.59
Phosphatase alkaline (units/L) 93.56 86.61 93.59 86.71
Bilirubin (mg/100 mL)   0.68   0.67   0.50   0.51
LDH (units/L)    258.22   265.45    307.63  299.30
Serum creatinine (mg/100 mL)   0.95   0.95   0.90   0.93
Urea/BUN (mg/100 mL) 35.23 34.64 35.90 33.75
Total Proteins (g/100 mL)   7.17   7.06   7.18   7.08
Albumin (g/100 mL)   4.16   4.11   4.13   4.12
Na+ (mmol/L    138.10   139.20    138.11  139.10
K+ (mmol/L)   4.17   4.24   4.34   4.28
Glucose (mg/100 mL) 91.53 89.54 83.53 85.88
Iron (μg/dL) 70.27 69.00 78.56 84.82
Orosomucoid (mg/100 mL) 85.19 90.98 98.06 89.98
CRP (mg/L)   5.37   4.27   5.20   4.85
Group A: Mesalamine + NAC; Group B: Mesalamine + placebo.
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 COMMENTS
Innovations and breakthroughs
Local overexpression of MCP-1 and IL-8 was associated with inflammation in 
UC and a decrease of colonic IL-8 has been reported during active UC. Our 
results show that antioxidant therapy with NAC decreases the levels of IL-8 that 
activates the recruitment and activation of neutrophils to the inflamed mucosa. It 
is suggested that higher dose or targeted NAC can alleviate colonic inflammation 
and hopefully become a novel agent for the treatment of UC.
Peer review
This is an excellent research paper which highlights the dual role antioxidants play 
in the pathogenesis of ulcerative colitis. And this is the first paper to cite radical 
induction theory which logically explains why the addition of NAC to conventional 
5-ASA therapy significantly increases the remission rate observed in ulcerative 
colitis. The findings are potentially important for planning of furthers studies (e.g. 
with higher dose of N-acetyl-L-cysteine; more homogenous groups of comparison, 
larger sample size, et cetera).
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